Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Jan;87(1):138–143. doi: 10.1111/j.1365-2249.1992.tb06427.x

In vivo activation of complement by IgA in a rat model.

R K Stad 1, W M Bogers 1, M E Thoomes-van der Sluys 1, L A Van Es 1, M R Daha 1
PMCID: PMC1554236  PMID: 1733628

Abstract

In this study we investigated the capacity of rat IgA to activate complement (C) in vivo in a rat model. Rat monomeric (m-), dimeric (d-) and polymeric (p-) IgA MoAbs were injected intravenously and assessed for deposition of C3 and C4 on IgA. By ELISA it was shown that both d- and p-IgA bound C3 whereas no binding of C3 by m-IgA was observed. Polymeric IgA was more efficient in binding of C3 as compared with d-IgA. However, in haemolytic assays no consistent decrease of plasma complement levels was observed except for dimeric IgA which induced a marginal consumption of AP50. When rats were pre-treated with cobra venom factor (CVF) to deplete C3, no C3 deposition was found on m-, d- or p-IgA. Neither m- nor d- or p-IgA was able to bind C4 in vivo. In agreement with the results described above, large sized polymeric IgA was shown to be taken up by Kupffer cells (KC) together with C3. No C3 was detected when rats were depleted of C using CVF. Taken together, the experimental data suggest that d- and p-IgA are able to activate C via the alternative pathway in vivo.

Full text

PDF
138

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger J. IgA glomerular deposits in renal disease. Transplant Proc. 1969 Dec;1(4):939–944. [PubMed] [Google Scholar]
  2. Bogers W. M., Stad R. K., Janssen D. J., Rits M., Bazin H., Van Es L. A., Daha M. R. Complement enhances the clearance of large-sized soluble IgA aggregates in rats. Eur J Immunol. 1991 May;21(5):1093–1099. doi: 10.1002/eji.1830210502. [DOI] [PubMed] [Google Scholar]
  3. Bohnsack J. F., Hawley M. M., Pritchard D. G., Egan M. L., Shigeoka A. O., Yang K. D., Hill H. R. An IgA monoclonal antibody directed against type III antigen on group B streptococci acts as an opsonin. J Immunol. 1989 Nov 15;143(10):3338–3342. [PubMed] [Google Scholar]
  4. Burritt M. F., Calvanico N. J., Mehta S., Tomasi T. B., Jr Activation of the classical complement pathway by Fc fragment of human IgA. J Immunol. 1977 Feb;118(2):723–725. [PubMed] [Google Scholar]
  5. Czerkinsky C., Koopman W. J., Jackson S., Collins J. E., Crago S. S., Schrohenloher R. E., Julian B. A., Galla J. H., Mestecky J. Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest. 1986 Jun;77(6):1931–1938. doi: 10.1172/JCI112522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dijkstra C. D., Döpp E. A., Joling P., Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology. 1985 Mar;54(3):589–599. [PMC free article] [PubMed] [Google Scholar]
  7. Evans D. J., Williams D. G., Peters D. K., Sissons J. G., Boulton-Jones J. M., Ogg C. S., Cameron J. S., Hoffbrand B. I. Glomerular deposition of properdin in Henoch-Schönlein syndrome and idiopathic focal nephritis. Br Med J. 1973 Aug 11;3(5875):326–328. doi: 10.1136/bmj.3.5875.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Faille-Kuyber E. H., Kater L., Kooiker C. J., Dorhout Mees E. J. IgA-deposits in cutaneous blood-vessel walls and mesangium in Henoch-Schönlein syndrome. Lancet. 1973 Apr 21;1(7808):892–893. doi: 10.1016/s0140-6736(73)91471-2. [DOI] [PubMed] [Google Scholar]
  9. Gaither T. A., Alling D. W., Frank M. M. A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol. 1974 Aug;113(2):574–583. [PubMed] [Google Scholar]
  10. Hall R. P., Lawley T. J. Characterization of circulating and cutaneous IgA immune complexes in patients with dermatitis herpetiformis. J Immunol. 1985 Sep;135(3):1760–1765. [PubMed] [Google Scholar]
  11. Hiemstra P. S., Gorter A., Stuurman M. E., Van Es L. A., Daha M. R. Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol. 1987 Mar;17(3):321–326. doi: 10.1002/eji.1830170304. [DOI] [PubMed] [Google Scholar]
  12. Hietanen J., Reunala T. IgA deposits in the oral mucosa of patients with dermatitis herpetiformis and linear IgA disease. Scand J Dent Res. 1984 Jun;92(3):230–234. doi: 10.1111/j.1600-0722.1984.tb00884.x. [DOI] [PubMed] [Google Scholar]
  13. Imai H., Chen A., Wyatt R. J., Rifai A. Composition of IgA immune complexes precipitated with polyethylene glycol. A model for isolation and analysis of immune complexes. J Immunol Methods. 1987 Nov 5;103(2):239–245. doi: 10.1016/0022-1759(87)90295-x. [DOI] [PubMed] [Google Scholar]
  14. Imai H., Chen A., Wyatt R. J., Rifai A. Lack of complement activation by human IgA immune complexes. Clin Exp Immunol. 1988 Sep;73(3):479–483. [PMC free article] [PubMed] [Google Scholar]
  15. Jarvis G. A., Griffiss J. M. Human IgA1 initiates complement-mediated killing of Neisseria meningitidis. J Immunol. 1989 Sep 1;143(5):1703–1709. [PubMed] [Google Scholar]
  16. Julian B. A., Wyatt R. J., McMorrow R. G., Galla J. H. Serum complement proteins in IgA nephropathy. Clin Nephrol. 1983 Nov;20(5):251–258. [PubMed] [Google Scholar]
  17. Khalfan H., Abuknesha R., Rand-Weaver M., Price R. G., Robinson D. Aminomethyl coumarin acetic acid: a new fluorescent labelling agent for proteins. Histochem J. 1986 Sep;18(9):497–499. doi: 10.1007/BF01675617. [DOI] [PubMed] [Google Scholar]
  18. Kijlstra A., Van Es L. A., Daha M. R. Enhanced degradation of soluble immunoglobulin aggregates by macrophages in the presence of complement. Immunology. 1979 Jul;37(3):673–680. [PMC free article] [PubMed] [Google Scholar]
  19. Lucisano Valim Y. M., Lachmann P. J. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol. 1991 Apr;84(1):1–8. doi: 10.1111/j.1365-2249.1991.tb08115.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pfaffenbach G., Lamm M. E., Gigli I. Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes. J Exp Med. 1982 Jan 1;155(1):231–247. doi: 10.1084/jem.155.1.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rauterberg E. W., Lieberknecht H. M., Wingen A. M., Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int. 1987 Mar;31(3):820–829. doi: 10.1038/ki.1987.72. [DOI] [PubMed] [Google Scholar]
  22. Rifai A., Chen A., Imai H. Complement activation in experimental IgA nephropathy: an antigen-mediated process. Kidney Int. 1987 Dec;32(6):838–844. doi: 10.1038/ki.1987.284. [DOI] [PubMed] [Google Scholar]
  23. Rits M., Cormont F., Bazin H., Meykens R., Vaerman J. P. Rat monoclonal antibodies. VI. Production of IgA secreting hybridomas with specificity for the 2,4-dinitrophenyl (DNP) hapten. J Immunol Methods. 1986 May 1;89(1):81–87. doi: 10.1016/0022-1759(86)90034-7. [DOI] [PubMed] [Google Scholar]
  24. Rits M., Hiemstra P. S., Bazin H., Van Es L. A., Vaerman J. P., Daha M. R. Activation of rat complement by soluble and insoluble rat IgA immune complexes. Eur J Immunol. 1988 Dec;18(12):1873–1880. doi: 10.1002/eji.1830181202. [DOI] [PubMed] [Google Scholar]
  25. Rits M., Kints J. P., Bazin H., Vaerman J. P. Rat C3 conversion by rat anti-2,4,dinitrophenyl (DNP) hapten IgA immune precipitates. Scand J Immunol. 1987 Apr;25(4):359–366. doi: 10.1111/j.1365-3083.1987.tb02201.x. [DOI] [PubMed] [Google Scholar]
  26. Roord J. J., Daha M., Kuis W., Verbrugh H. A., Verhoef J., Zegers B. J., Stoop J. W. Inherited deficiency of the third component of complement associated with recurrent pyogenic infections, circulating immune complexes, and vasculitis in a Dutch family. Pediatrics. 1983 Jan;71(1):81–87. [PubMed] [Google Scholar]
  27. Russell M. W., Mansa B. Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA. Scand J Immunol. 1989 Aug;30(2):175–183. doi: 10.1111/j.1365-3083.1989.tb01199.x. [DOI] [PubMed] [Google Scholar]
  28. Schneiderman R. D., Lint T. F., Knight K. L. Activation of the alternative pathway of complement by twelve different rabbit-mouse chimeric transfectoma IgA isotypes. J Immunol. 1990 Jul 1;145(1):233–237. [PubMed] [Google Scholar]
  29. Vaerman J. P., André C., Bazin H., Heremans J. F. Mesenteric lymph as a major source of serum IgA in guinea pigs and rats. Eur J Immunol. 1973 Sep;3(9):580–584. doi: 10.1002/eji.1830030911. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES